当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2019-12-24 , DOI: 10.1021/acs.jmedchem.9b01180
Brian A. Lanman , Jennifer R. Allen , John G. Allen , Albert K. Amegadzie , Kate S. Ashton , Shon K. Booker , Jian Jeffrey Chen , Ning Chen , Michael J. Frohn , Guy Goodman , David J. Kopecky , Longbin Liu , Patricia Lopez , Jonathan D. Low , Vu Ma , Ana E. Minatti , Thomas T. Nguyen , Nobuko Nishimura , Alexander J. Pickrell , Anthony B. Reed , Youngsook Shin , Aaron C. Siegmund , Nuria A. Tamayo , Christopher M. Tegley , Mary C. Walton , Hui-Ling Wang , Ryan P. Wurz , May Xue , Kevin C. Yang , Pragathi Achanta , Michael D. Bartberger , Jude Canon , L. Steven Hollis , John D. McCarter , Christopher Mohr , Karen Rex , Anne Y. Saiki , Tisha San Miguel , Laurie P. Volak , Kevin H. Wang , Douglas A. Whittington , Stephan G. Zech , J. Russell Lipford , Victor J. Cee

KRASG12C has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clinical trials (NCT03600883).

中文翻译:

发现用于治疗实体瘤的KRASG12C(AMG 510)共价抑制剂。

KRASG12C已成为治疗实体瘤的有希望的靶标。靶向突变半胱氨酸12残基的共价抑制剂已显示出可以通过这个长期的“不可吸收的”靶标破坏信号传导。然而,尚未确定临床上可行的抑制剂。在这里,我们报告了开发利用我们在KRASG12C中鉴定出的隐窝(H95 / Y96 / Q99)的努力,以鉴定适合临床开发的抑制剂。描述了基于结构的设计努力,该努力导致鉴定了新颖的喹唑啉酮支架,以及克服了围绕轴向手性联芳基键旋转受限而引起的构型稳定性问题的优化努力。对产生的潜在生物进行生物制药优化,最终鉴定出了AMG 510,这是一种高效,选择性强,
更新日期:2019-12-25
down
wechat
bug